felin
caliciviru
fcv
highli
contagi
pathogen
caus
oral
upper
respiratori
tract
diseas
cat
despit
widespread
vaccin
preval
fcv
remain
high
furthermor
high
gene
mutat
rate
led
emerg
variant
infect
lethal
date
effect
antivir
drug
avail
treat
fcv
infect
show
lithium
chlorid
licl
effect
suppress
replic
fcv
strain
crandellrees
felin
kidney
crfk
cell
antivir
activ
licl
occur
primarili
earli
stage
infect
dosedepend
manner
licl
treatment
also
inhibit
cytopath
effect
licl
treatment
exhibit
strong
inhibitori
effect
panel
two
refer
strain
two
recent
fcv
isol
china
result
demonstr
licl
might
effect
antifcv
drug
control
fcv
diseas
studi
requir
explor
antivir
activ
licl
fcv
replic
vivo
calicivirus
small
nonenvelop
positivestrand
rna
virus
belong
famili
calicivirida
divid
five
genera
noroviru
sapoviru
lagoviru
neboviru
vesiviru
genu
vesiviru
includ
felin
caliciviru
highli
contagi
pathogen
widespread
distribut
felin
popul
oral
ulcer
upper
respiratori
symptom
high
fever
main
clinic
sign
fcvinfect
kitten
follow
subclin
syndrom
includ
chronic
stomat
pneumon
limp
syndrom
cat
virul
system
fcv
diseas
variabl
show
pyrexia
cutan
edema
ulcer
lesion
head
limb
jaundic
diseas
sever
adult
cat
higher
mortal
addit
persist
infect
lead
high
preval
fcv
rang
approxim
gener
cat
popul
much
coloni
therefor
treat
prevent
fcv
infect
challeng
fcv
exhibit
one
highest
evolutionari
rate
among
virus
inde
evolutionari
rate
variabl
region
capsid
protein
estim
substitut
per
nucleotid
per
year
accordingli
older
vaccin
provid
crossprotect
newer
strain
addit
genet
antigen
landscap
highli
complex
geograph
locat
thu
vaccin
applic
must
base
assess
situat
local
nation
level
fcv
vaccin
gener
effect
reduc
sever
durat
clinic
sign
prevent
infect
shed
given
insuffici
fcv
vaccin
necessari
develop
safe
effect
antivir
drug
monotherapi
combin
treatment
addit
signific
felin
health
fcv
frequent
use
model
human
norovirus
import
caus
vomit
diarrhea
peopl
sever
type
therapeut
treatment
fcv
report
felinecalicivirusspecif
antivir
phosphorodiamid
morpholino
oligom
pmo
test
natur
occur
outbreak
fcv
result
demonstr
pmo
work
higheffici
drug
treat
fcv
diseas
mefloquin
employ
monotherapi
combin
treatment
rfeifnx
defici
number
drug
metabol
pathway
recogn
human
fifti
year
lithium
chlorid
licl
use
major
treatment
bipolar
disord
mechan
licl
explor
particularli
treat
alzheim
diseas
diabet
serou
ovarian
cancer
also
antimicrobi
agent
studi
demonstr
licl
inhibit
replic
virus
herp
simplex
viru
coronaviru
infecti
bronchiti
viru
porcin
reproduct
respiratori
syndrom
prr
suppress
inflammatori
respons
modul
cell
apoptosi
restor
host
protein
synthesi
infect
cell
howev
remain
unknown
whether
licl
inhibit
fcv
replic
studi
antivir
activ
licl
fcv
investig
vitro
found
licl
inhibit
fcv
replic
dosedepend
manner
crandellrees
felin
kidney
crfk
cell
atcc
grown
dulbecco
modifi
eagl
medium
dmem
gibco
supplement
fetal
bovin
serum
fb
u
penicillin
lg
streptomycin
per
ml
fcv
strain
bolin
purchas
atcc
hrbss
strain
fcv
genbank
access
describ
previous
strain
isol
haerbin
china
sequenc
publish
isol
hrbss
sick
pet
cat
crfk
cell
grown
co
incub
use
propag
fcv
viru
stock
centrifug
g
min
remov
cell
debri
store
viru
stock
titrat
use
tcid
tissu
cultureinfect
dose
assay
licl
purchas
sigmaaldrich
sigma
st
loui
mo
usa
prepar
dmem
concentr
steril
passag
filter
confluent
crfk
cell
monolay
plate
cell
incub
overnight
co
complet
medium
cell
supernat
remov
monolay
overlaid
licl
seri
concentr
mm
serumfre
dmem
h
h
monolay
wash
pb
mocktreat
crfk
cell
serv
control
cytotox
assay
perform
accord
instruct
manufactur
cell
count
donjindo
japan
wash
pb
crfk
cell
incub
medium
llwell
solut
llwell
h
optic
densiti
od
measur
wavelength
nm
use
multimod
plate
reader
pe
usa
rel
cell
viabil
rate
determin
percentag
concentr
od
drug
od
control
licl
concentr
cytostat
concentr
cc
defin
nontox
concentr
evalu
whether
licl
affect
attach
fcv
crfk
cell
crfk
cell
plate
incub
overnight
co
complet
medium
nontox
concentr
mm
licl
mix
fcv
solut
incub
h
mixtur
inocul
onto
cell
h
multipl
infect
moi
tcid
cell
remov
upper
mixtur
total
rna
extract
monolay
subject
realtim
pcr
rel
viral
rna
level
calcul
evalu
whether
licl
affect
entri
fcv
crfk
cell
crfk
cell
plate
incub
overnight
co
complet
medium
cell
supernat
remov
monolay
infect
fcv
solut
moi
tcid
cell
contain
differ
concentr
licl
mm
h
incub
h
remov
upper
mixtur
total
rna
extract
monolay
subject
realtim
pcr
rel
viral
rna
level
calcul
evalu
whether
licl
affect
replic
fcv
crfk
cell
crfk
cell
plate
incub
overnight
complet
medium
cell
supernat
remov
monolay
infect
fcv
moi
tcid
cell
h
remov
upper
mixtur
wash
pb
monolay
cover
licl
llwell
mm
incub
h
cytopath
effect
cpe
h
postinfect
assess
cell
supernat
collect
measur
viru
titer
remov
upper
mixtur
total
rna
extract
monolay
subject
realtim
pcr
rel
viral
rna
level
calcul
compar
antivir
activ
pretreat
simultan
treatment
posttreat
crfk
cell
plate
incub
overnight
complet
medium
pretreat
monolay
inocul
mm
licl
h
infect
fcv
moi
tcid
cell
simultan
treatment
mm
licl
fcv
incub
cell
h
posttreat
monolay
infect
fcv
moi
tcid
cell
inocul
mm
licl
llwell
h
postinfect
durat
exposur
compound
pretreat
assay
h
prior
infect
assay
endpoint
simultaneoustreat
assay
time
infect
assay
endpoint
cell
supernat
collect
viru
titrat
h
postinfect
total
rna
extract
monolay
subject
realtim
pcr
rel
viral
rna
level
calcul
crfk
cell
plate
incub
overnight
complet
medium
mixtur
mm
licl
fcv
moi
tcid
cell
incub
cell
h
durat
exposur
compound
assay
time
infect
assay
endpoint
cell
collect
h
postinocul
total
rna
extract
monolay
subject
realtim
pcr
rel
viral
rna
level
calcul
antivir
efficaci
field
isol
refer
strain
fcv
crfk
cell
plate
incub
overnight
complet
medium
monolay
inocul
mm
licl
h
infect
fcv
bolin
hrbss
moi
tcid
cell
durat
exposur
compound
assay
h
prior
infect
assay
endpoint
cell
supernat
collect
viru
titrat
h
postinfect
briefli
tenfold
dilut
prepar
ml
dilut
ad
well
microtit
plate
h
viral
adsorpt
medium
remov
fresh
dmem
contain
fb
iu
penicillinml
lg
streptomycinml
ad
well
viral
titer
determin
cytopathi
h
postinocul
express
median
tissu
cultur
infect
dose
log
tcid
ml
accord
method
reed
total
rna
fcvinfect
cell
prepar
axygen
multisourc
total
rna
miniprep
kit
accord
manufactur
instruct
cdna
obtain
use
one
step
primescript
tm
rtpcr
kit
takara
japan
realtim
quantit
pcr
target
propol
gene
fcv
carri
use
lightcycl
sybr
green
master
roch
swit
accord
manufactur
instruct
rel
mrna
express
level
calcul
ddct
method
use
gadph
intern
control
normal
mean
mrna
level
mocktreat
group
set
follow
primer
use
fcvforward
wash
pb
crfk
cell
fix
paraformaldehyd
pb
min
permeabil
triton
pb
min
wash
crfk
cell
incub
cat
antifcv
antibodi
h
subsequ
fitcconjug
affinipur
goat
anticat
igg
jackson
usa
use
secondari
antibodi
wash
three
time
pb
dapi
ad
sampl
incub
room
temperatur
min
wash
fluoresc
observ
amg
evo
invert
microscop
amg
usa
experi
perform
triplic
repeat
three
independ
experi
data
present
mean
standard
deviat
sd
signific
differ
experiment
group
determin
pair
ttest
oneway
anova
use
prism
softwar
graphpad
softwar
pvalu
select
indic
signific
cytotox
assay
perform
accord
instruct
manufactur
kit
rel
cell
viabil
treatment
licl
concentr
mm
h
h
wherea
viabil
treatment
mm
licl
h
h
fig
necessari
verifi
concentr
licl
nontox
cell
ensur
result
experi
unaffect
drug
licl
concentr
cytostat
concentr
cc
inhibit
prolifer
exponenti
grow
cell
defin
nontox
concentr
concentr
mm
licl
cc
valu
differ
cell
morpholog
compar
mocktreat
cell
observ
data
shown
concentr
therefor
chosen
maximum
concentr
licl
antivir
assay
evalu
whether
licl
affect
fcv
attach
crfk
cell
nontox
concentr
mm
licl
mix
fcv
suspens
inocul
onto
cell
incub
h
remov
upper
mixtur
rel
viral
rna
level
calcul
realtim
pcr
result
show
treatment
licl
concentr
mm
significantli
affect
rel
fcv
genom
rna
level
compar
mocktreat
crfk
cell
fig
indic
licl
effect
attach
fcv
crfk
cell
viral
entri
assay
monolay
infect
fcv
moi
tcid
cell
h
cover
differ
concentr
mm
licl
llwell
incub
h
remov
upper
mixtur
rel
viral
rna
level
calcul
realtim
pcr
shown
fig
rel
fcv
genom
rna
level
group
approxim
also
signific
differ
mocktreat
crfk
cell
cell
treat
mm
licl
fig
indic
licl
effect
fcv
entri
crfk
cell
analyz
effect
differ
licl
concentr
fcv
replic
crfk
cell
monolay
infect
fcv
moi
tcid
cell
h
cover
licl
llwell
mm
incub
h
cpe
viru
titer
cell
supernat
viral
rna
level
analyz
h
postinfect
although
treatment
mm
licl
inhibit
cpe
fig
treatment
mm
licl
significantli
inhibit
cpe
fig
addit
cpe
ratio
declin
concentr
licl
gradual
increas
mm
fig
rel
viral
rna
level
cell
treat
mm
licl
respect
compar
mocktreat
cell
fig
indic
licl
treatment
suppress
synthesi
viral
rna
furthermor
viru
titer
cell
treat
mm
licl
decreas
compar
mock
treatment
fig
although
treatment
mm
licl
significantli
inhibit
fcv
replic
fig
treatment
mm
licl
led
approxim
decreas
regard
ifa
strong
fluoresc
signal
observ
crfk
cell
infect
fcv
without
licl
treatment
h
postinfect
signal
declin
cell
treat
mm
licl
fig
fluoresc
signal
detect
mockinfect
cell
timeofaddit
experi
carri
explor
detail
effect
licl
treatment
viral
replic
crfk
cell
treat
mm
licl
differ
time
point
fcv
entri
viral
rna
bare
detect
h
postinfect
fig
rel
viral
rna
level
h
h
h
postinfect
fig
cytotox
effect
licl
treatment
crfk
cell
cell
treat
mm
licl
h
h
rel
cell
viabil
determin
assay
normal
valu
mm
group
set
data
express
mean
standard
deviat
sd
three
independ
experi
respect
drugtreat
cell
fig
contrast
control
replic
viru
significantli
decreas
addit
licl
h
postinfect
signific
reduct
occur
h
postinfect
fig
agre
result
rel
viral
rna
level
thu
signific
inhibitori
effect
licl
fcv
replic
occur
primarili
earli
stage
examin
whether
inhibit
effici
would
increas
increas
durat
licl
treatment
rel
viral
rna
level
determin
h
postinocul
compar
mock
treatment
group
viral
replic
significantli
inhibit
time
point
examin
fig
mean
rel
viral
rna
level
h
h
h
postinfect
respect
drugtreat
cell
fig
inhibit
effici
h
h
postinocul
higher
h
postinocul
result
indic
antivir
effici
licl
fcv
infect
increas
increas
treatment
time
licl
strongli
inhibit
cpe
induc
refer
strain
fcv
well
replic
vitro
assess
efficaci
licl
differ
isol
experi
cell
treat
licl
h
infect
valu
repres
mean
sd
three
independ
experi
asterisk
indic
signific
differ
mocktreat
drugtreat
group
p
p
p
conduct
use
field
isol
refer
strain
follow
h
exposur
licl
mock
treatment
crfk
cell
infect
strain
bolin
hrbss
moi
tcid
cell
h
cover
mm
licl
well
h
viru
titer
cell
supernat
analyz
h
postinfect
result
show
licl
strongli
inhibit
replic
refer
strain
fcv
bolin
field
isol
hrbss
fig
compar
mock
treatment
licl
pretreat
led
nearli
tenfold
decreas
infect
field
isol
hrbss
fig
result
demonstr
licl
could
inhibit
growth
refer
strain
field
isol
vitro
previou
studi
demonstr
licl
antivir
effect
herp
simplex
viru
porcin
parvoviru
infecti
bronchiti
viru
ibv
transmiss
gastroenter
viru
tgev
howev
inhibit
observ
influenza
virus
encephalomyocard
viru
studi
show
licl
effect
suppress
replic
fcv
strain
crfk
cell
inhibitori
effect
licl
occur
primarili
earli
stage
dose
depend
licl
treatment
also
reduc
fcvinduc
cytopath
effect
result
demonstr
licl
might
effect
antifcv
drug
control
fcv
diseas
studi
requir
explor
antivir
activ
licl
fcv
replic
vivo
studi
found
licl
effect
attach
entri
everi
concentr
test
although
signific
inhibitori
effect
replic
observ
inhibit
licl
occur
primarili
earli
stage
dose
depend
licl
treatment
also
inhibit
cytopath
effect
fcv
result
consist
inhibitori
effect
licl
virus
transmiss
gastroenter
coronaviru
infecti
bronchiti
viru
indic
antivir
effect
licl
may
gener
featur
drug
certain
virus
eg
coronavirus
although
frequenc
fcv
gene
mutat
high
fcv
strain
belong
serotyp
addit
well
anoth
seven
fcv
strain
show
sensit
antivir
drug
mefloquin
antivir
effici
vari
differ
fcv
strain
infect
licl
could
function
current
circul
virus
china
found
viabil
crfk
cell
affect
licl
concentr
rang
mm
addit
concentr
licl
increas
mm
mm
viabil
crfk
cell
decreas
less
h
postinocul
howev
viabil
decreas
h
postinocul
fcv
strain
replic
spread
rapidli
fcvinduc
cpe
crfk
cell
obviou
h
postinfect
moi
nearli
cell
becom
round
slough
h
postinfect
thu
reason
use
high
dose
licl
evalu
antivir
effect
fcv
replic
vitro
high
concentr
licl
blood
caus
side
toxic
effect
symptom
associ
gener
mild
includ
tremor
nausea
diarrhea
vertigo
confus
howev
higher
lithium
level
h
durat
exposur
compound
assay
time
infect
assay
endpoint
cell
collect
h
postinocul
total
rna
extract
monolay
subject
realtim
pcr
rel
viral
rna
level
calcul
valu
repres
mean
sd
three
independ
experi
asterisk
indic
signific
differ
mocktreat
drugtreat
group
p
p
fig
antivir
efficaci
licl
refer
stain
recent
field
isol
fcv
china
cell
pretreat
mm
licl
h
prior
infect
fcv
bolin
hrbss
moi
viru
titr
calcul
h
postinfect
use
tcid
endpoint
assay
valu
repres
mean
sd
three
independ
experi
asterisk
indic
signific
differ
mocktreat
drugtreat
group
p
plasma
rare
lead
persist
neurolog
deficit
lithium
appear
carcinogen
mutagen
may
lead
renal
liver
damag
prolong
exposur
serum
level
mm
specif
inhibitor
glycogen
synthas
licl
caus
inhibit
compet
nativ
mg
metalbind
site
licl
regul
multipl
biolog
process
consid
nonspecif
inhibitor
licl
shown
effect
suppress
replic
apoptosi
inflammatori
cytokin
product
interleukin
infect
cell
howev
licl
attenu
lp
poli
c
sendaivirusinduc
ifnb
product
manner
macrophag
appear
contradictori
regard
antivir
effect
licl
licl
wide
use
longterm
mood
stabil
treatment
psychiatr
diseas
due
inhibit
multifunct
kinas
involv
cellular
process
includ
glycogen
metabol
cell
prolifer
neuron
function
oncogenesi
develop
recent
studi
provid
evid
involv
innat
immun
respons
also
crucial
regul
balanc
proand
antiinflammatori
cytokin
product
peripher
central
nervou
system
influenc
tcell
prolifer
differenti
surviv
licl
specif
inhibitor
enzym
belong
gsk
famili
also
pyruv
kinas
polyphosph
inositol
monophosph
precis
mechan
antivir
effect
licl
need
investig
studi
reveal
licl
act
potent
inhibitor
fcv
vitro
antivir
activ
occur
dosedepend
manner
earli
phase
viral
replic
first
report
antivir
activ
licl
caliciviru
expand
antivir
spectrum
viru
investig
optim
compound
clinic
use
treat
fcv
infect
perform
consider
given
investig
effect
licl
virus
cat
